Crystal Company Profile
What is the competitive landscape for CRYSTAL
CRYSTAL has one approved drug.
Summary for Crystal
| US Patents: | 0 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Crystal: | See patent lawsuits for Crystal |
Drugs and US Patents for Crystal
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crystal | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213605-003 | May 28, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Crystal | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213605-002 | May 28, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Crystal | SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213605-001 | May 28, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
